$FBRX
Forte Biosciences, Inc.

2018 Q1 Form 10-K Financial Statement

#000156459018005132 Filed on March 09, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 2016 Q4
Revenue $0.00 $41.00K $10.00K
YoY Change -16.33% 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.420M $8.560M $1.350M
YoY Change 24.74% 89.38% 40.63%
% of Gross Profit
Research & Development $10.44M $29.11M $6.630M
YoY Change 57.55% 6.96% 15.91%
% of Gross Profit
Depreciation & Amortization $95.00K $292.0K $70.00K
YoY Change 46.15% 14.51% 16.67%
% of Gross Profit
Operating Expenses $12.86M $37.67M $7.985M
YoY Change 50.11% 18.68% 19.54%
Operating Profit -$12.85M -$37.63M
YoY Change 50.19% 18.74%
Interest Expense -$30.00K -$1.300M -$460.0K
YoY Change -94.23% -29.35% 155.56%
% of Operating Profit
Other Income/Expense, Net -$34.00K -$1.300M
YoY Change -93.46% -27.25%
Pretax Income -$12.88M -$38.93M -$8.430M
YoY Change 42.01% 16.28% 23.07%
Income Tax $1.000K $0.00
% Of Pretax Income
Net Earnings -$12.88M -$38.93M -$8.430M
YoY Change 41.96% 16.28% 23.07%
Net Earnings / Revenue -94948.78% -84300.0%
Basic Earnings Per Share
Diluted Earnings Per Share -$9.684M -$40.13M -$6.854M
COMMON SHARES
Basic Shares Outstanding 19.91M
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q1 2017 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $74.00M $88.70M $31.25M
YoY Change 156.18% 184.29% -46.95%
Cash & Equivalents $17.79M $35.90M $5.510M
Short-Term Investments $56.21M $52.80M $25.74M
Other Short-Term Assets $3.100M $1.900M $1.200M
YoY Change 158.33% 58.33% -7.69%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $77.10M $90.60M $32.46M
YoY Change 156.67% 178.77% -46.08%
LONG-TERM ASSETS
Property, Plant & Equipment $1.400M $1.200M $743.0K
YoY Change 90.74% 71.43% 85.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $200.0K $200.0K $2.147M
YoY Change -94.32% -90.48% 43.13%
Total Long-Term Assets $1.600M $1.500M $2.890M
YoY Change -62.41% -48.28% 44.5%
TOTAL ASSETS
Total Short-Term Assets $77.10M $90.60M $32.46M
Total Long-Term Assets $1.600M $1.500M $2.890M
Total Assets $78.70M $92.10M $35.35M
YoY Change 129.49% 160.17% -43.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.800M $2.000M $1.666M
YoY Change 90.07% 17.65% 28.15%
Accrued Expenses $7.900M $8.100M $5.437M
YoY Change 0.56% 50.0% 39.41%
Deferred Revenue $36.00K
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $7.200M $7.200M $7.200M
YoY Change 0.0% 0.0% 1100.0%
Total Short-Term Liabilities $16.90M $17.30M $14.38M
YoY Change 5.13% 20.14% 143.76%
LONG-TERM LIABILITIES
Long-Term Debt $2.000M $3.600M $10.24M
YoY Change -76.7% -73.91% -39.76%
Other Long-Term Liabilities $200.0K $0.00 $100.0K
YoY Change 100.0% -100.0% 0.0%
Total Long-Term Liabilities $2.200M $3.600M $10.24M
YoY Change -74.37% -74.29% -40.11%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.90M $17.30M $14.38M
Total Long-Term Liabilities $2.200M $3.600M $10.24M
Total Liabilities $19.06M $21.00M $28.36M
YoY Change -46.76% -26.06% 22.75%
SHAREHOLDERS EQUITY
Retained Earnings -$179.8M -$128.0M
YoY Change 31.18%
Common Stock $239.6M $3.583M
YoY Change 5669.2%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $59.68M $71.10M -$124.4M
YoY Change
Total Liabilities & Shareholders Equity $78.74M $92.10M $35.35M
YoY Change 129.6% 160.17% -43.17%

Cashflow Statement

Concept 2018 Q1 2017 2016 Q4
OPERATING ACTIVITIES
Net Income -$12.88M -$38.93M -$8.430M
YoY Change 41.96% 16.28% 23.07%
Depreciation, Depletion And Amortization $95.00K $292.0K $70.00K
YoY Change 46.15% 14.51% 16.67%
Cash From Operating Activities -$12.71M -$31.13M -$7.750M
YoY Change 67.87% 5.4% 8.24%
INVESTING ACTIVITIES
Capital Expenditures $220.0K $655.0K -$10.00K
YoY Change 315.09% 24.76% -80.0%
Acquisitions
YoY Change
Other Investing Activities -$3.440M -$27.05M $6.850M
YoY Change -190.05% -207.81% -193.58%
Cash From Investing Activities -$3.661M -$27.71M $6.840M
YoY Change -197.11% -212.78% -192.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $29.00K $507.0K
YoY Change -29.27% 4970.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.771M 89.26M 2.330M
YoY Change -133.8% 3727.74% -86.2%
NET CHANGE
Cash From Operating Activities -12.71M -31.13M -7.750M
Cash From Investing Activities -3.661M -27.71M 6.840M
Cash From Financing Activities -1.771M 89.26M 2.330M
Net Change In Cash -18.14M 30.42M 1.420M
YoY Change -1359.72% -1252.39% -39.32%
FREE CASH FLOW
Cash From Operating Activities -$12.71M -$31.13M -$7.750M
Capital Expenditures $220.0K $655.0K -$10.00K
Free Cash Flow -$12.93M -$31.79M -$7.740M
YoY Change 69.59% 5.73% 8.86%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017 dei Amendment Flag
AmendmentFlag
false
CY2017 dei Document Period End Date
DocumentPeriodEndDate
2017-12-31
CY2017 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2017 dei Document Type
DocumentType
10-K
CY2017 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
81000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
-92330000
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
571000
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1547000
CY2015 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1301000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
-70441000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-38929000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
20000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3581000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-166929000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-128000000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
71082000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
92073000
CY2016Q4 us-gaap Assets
Assets
35351000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1666000
CY2017 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2017 dei Trading Symbol
TradingSymbol
TOCA
CY2017 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2017 dei Entity Registrant Name
EntityRegistrantName
Tocagen Inc
CY2017 dei Entity Central Index Key
EntityCentralIndexKey
0001419041
CY2017 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35933000
CY2017Q4 us-gaap Marketable Securities
MarketableSecurities
52792000
CY2017Q4 us-gaap Assets
Assets
92073000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1951000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8120000
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10000
CY2017 us-gaap Interest Income Other
InterestIncomeOther
595000
CY2017 us-gaap Interest Expense Debt
InterestExpenseDebt
1932000
CY2016 us-gaap Interest Expense Debt
InterestExpenseDebt
2052000
CY2016 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-50000
CY2015 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-111000
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1300000
CY2016 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1787000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5437000
CY2017Q4 us-gaap Notes Payable Current
NotesPayableCurrent
7200000
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
36000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-23056000
CY2015 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-102000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-33478000
CY2016 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
23003000
CY2015 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
59870000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
655000
CY2017 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
43725000
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
45000
CY2017Q4 toca Deferred Grant Funding
DeferredGrantFunding
23000
CY2016Q4 toca Deferred Grant Funding
DeferredGrantFunding
34000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17330000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14382000
CY2017Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
3625000
CY2016Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
10241000
CY2016Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
3398000
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-38963000
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33420000
CY2018Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
19911616
CY2017Q2 dei Entity Public Float
EntityPublicFloat
217000000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5510000
CY2016Q4 us-gaap Marketable Securities
MarketableSecurities
25735000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1904000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1216000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
90629000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
32461000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1217000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
743000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
227000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2147000
CY2016Q4 us-gaap Notes Payable Current
NotesPayableCurrent
7200000
CY2016Q4 toca Convertible Promissory Notes Subscription Liability
ConvertiblePromissoryNotesSubscriptionLiability
140000
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
68000
CY2016Q4 toca Preferred Stock Warrant Liabilities
PreferredStockWarrantLiabilities
126000
CY2016Q4 us-gaap Liabilities
Liabilities
28355000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
131413000
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
238025000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-34000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-124417000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
35351000
CY2017Q4 us-gaap Related Party Transaction Due From To Related Party Noncurrent
RelatedPartyTransactionDueFromToRelatedPartyNoncurrent
0
CY2016Q4 us-gaap Related Party Transaction Due From To Related Party Noncurrent
RelatedPartyTransactionDueFromToRelatedPartyNoncurrent
-1025000
CY2016Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
51000000
CY2016Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
131720000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
77800000
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2202517
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2202517
CY2017 us-gaap Licenses Revenue
LicensesRevenue
41000
CY2016 us-gaap Licenses Revenue
LicensesRevenue
49000
CY2015 us-gaap Licenses Revenue
LicensesRevenue
51000
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27218000
CY2017 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-37000
CY2017 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-34000
CY2016 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
58000
CY2015 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-52000
CY2016 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
20000
CY2015 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
15000
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23108000
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.66
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-15.22
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-10.57
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14607609
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2199964
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2182032
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
157000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1062000
CY2015 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-52000
CY2015Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest Adjusted Balance1
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1
-92330000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1323000
CY2016 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
58000
CY2017 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
426000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4451000
CY2017 toca Conversion Of Preferred Stock To Common Stock Amount Converted
ConversionOfPreferredStockToCommonStockAmountConverted
131410000
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
86948000
CY2017 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
11057000
CY2017 toca Preferred Stock Warrants Liabilities Converted Into Warrants To Purchase Share Of Common Stock
PreferredStockWarrantsLiabilitiesConvertedIntoWarrantsToPurchaseShareOfCommonStock
89000
CY2017 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-34000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
4451000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
1323000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
1062000
CY2017 us-gaap Depreciation
Depreciation
292000
CY2016 us-gaap Depreciation
Depreciation
255000
CY2015 us-gaap Depreciation
Depreciation
232000
CY2017 toca Noncash Interest Expense
NoncashInterestExpense
590000
CY2016 toca Noncash Interest Expense
NoncashInterestExpense
570000
CY2015 toca Noncash Interest Expense
NoncashInterestExpense
94000
CY2017 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
19000
CY2016 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
9000
CY2015 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-5000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
679000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
157000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1072000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
304000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
586000
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2946000
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-41000
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-49000
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-51000
CY2017 toca Increase Decrease In Deferred Grant Funding
IncreaseDecreaseInDeferredGrantFunding
-11000
CY2016 toca Increase Decrease In Deferred Grant Funding
IncreaseDecreaseInDeferredGrantFunding
-57000
CY2015 toca Increase Decrease In Deferred Grant Funding
IncreaseDecreaseInDeferredGrantFunding
-2000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-31133000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-29539000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-21042000
CY2016 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
48095000
CY2015 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
35158000
CY2017 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
70797000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
525000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
231000
CY2017 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
20000
CY2015 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
15000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-27707000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
24567000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-24928000
CY2017 toca Proceeds From Offering Of Common Net Of Stock Issuance Costs
ProceedsFromOfferingOfCommonNetOfStockIssuanceCosts
88618000
CY2017 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
7338000
CY2016 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
3374000
CY2016 toca Proceeds From Convertible Promissory Note Subscriptions
ProceedsFromConvertiblePromissoryNoteSubscriptions
140000
CY2015 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
33075000
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
507000
CY2016 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
592000
CY2015 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
982000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
89263000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2332000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
49916000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
30423000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2640000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3946000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8150000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4204000
CY2017 us-gaap Interest Paid
InterestPaid
1210000
CY2016 us-gaap Interest Paid
InterestPaid
1460000
CY2015 us-gaap Interest Paid
InterestPaid
124000
CY2017 toca Convertible Preferred Stock Converted Into Shares Of Common Stock
ConvertiblePreferredStockConvertedIntoSharesOfCommonStock
131410000
CY2017 toca Convertible Promissory Notes Principal And Accrued Interest Converted Into Shares Of Common Stock
ConvertiblePromissoryNotesPrincipalAndAccruedInterestConvertedIntoSharesOfCommonStock
11057000
CY2015 toca Fair Value Of Preferred Stock Warrants Issued In Connection With Notes Payable
FairValueOfPreferredStockWarrantsIssuedInConnectionWithNotesPayable
287000
CY2017 toca Deferred Equity Issuance Cost Payment Reclassified Of Equity Effective Intial Public Offering
DeferredEquityIssuanceCostPaymentReclassifiedOfEquityEffectiveIntialPublicOffering
1574000
CY2017 toca Deferred Equity Issuance Costs Incurred But Not Yet Paid
DeferredEquityIssuanceCostsIncurredButNotYetPaid
96000
CY2017 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
111000
CY2016 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
28000
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The Company&#8217;s financial statements are prepared in accordance with accounting principles generally accepted in the United States (GAAP), which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and expenses and related disclosures during the reporting period. Significant estimates in the Company&#8217;s financial statements relate to clinical trial accruals, the valuation of equity awards, and the development period used for license revenue recognition. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results may differ from these estimates under different assumptions or conditions.</p></div>
CY2017 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Off-Balance Sheet Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash equivalents and marketable securities. The Company&#8217;s investment policy includes guidelines for the quality of the related institutions and financial instruments, and defines allowable investments that the Company may invest in, which the Company believes minimizes the exposure to concentration of credit risk.</p></div>
CY2017Q4 toca Working Capital
WorkingCapital
73300000
CY2017 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2017 us-gaap Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
more than 50 percent
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2600008
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8086581
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7439535
CY2017Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2016Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2017Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
52823000
CY2016Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
25735000
CY2016Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
6000
CY2017Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
31000
CY2016Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
6000
CY2017Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
52792000
CY2016Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
25735000
CY2017 us-gaap Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net
OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet
0
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3923000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3157000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2706000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2414000
CY2017Q4 toca Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
2809000
CY2016Q4 toca Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
2196000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2489000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
728000
CY2017Q4 toca Accrued Contract Manufacturing Services Current
AccruedContractManufacturingServicesCurrent
1536000
CY2016Q4 toca Accrued Contract Manufacturing Services Current
AccruedContractManufacturingServicesCurrent
1508000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
276000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
459000
CY2017Q4 toca Accrued Contract Research Services Current
AccruedContractResearchServicesCurrent
104000
CY2016Q4 toca Accrued Contract Research Services Current
AccruedContractResearchServicesCurrent
114000
CY2017Q4 us-gaap Interest Payable Current
InterestPayableCurrent
77000
CY2016Q4 us-gaap Interest Payable Current
InterestPayableCurrent
120000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
829000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
312000
CY2017Q2 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
11100000
CY2017Q2 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
1109176
CY2017Q2 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
10.00
CY2017 us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
In March 2017, the Company’s board of directors and stockholders approved a 1-for-6.9 reverse stock split of the Company’s outstanding common stock. The accompanying financial statements and notes to the financial statements give retroactive effect to the reverse stock split for all periods presented.
CY2017 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-6.9
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2194000
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1087000
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
862000
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
81000
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
10000
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
157000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
677000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
62000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
160000
CY2017 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
50121
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4451000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1323000
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1062000
CY2017 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2016 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2015 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2017 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2016 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2015 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.057
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.056
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.056
CY2017 toca Effective Income Tax Rate Reconciliation Permanent Adjustments
EffectiveIncomeTaxRateReconciliationPermanentAdjustments
-0.045
CY2016 toca Effective Income Tax Rate Reconciliation Permanent Adjustments
EffectiveIncomeTaxRateReconciliationPermanentAdjustments
-0.054
CY2015 toca Effective Income Tax Rate Reconciliation Permanent Adjustments
EffectiveIncomeTaxRateReconciliationPermanentAdjustments
-0.048
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.037
CY2017 toca Effective Income Tax Rate Reconciliation Net Operating Loss Carryovers Not Recognized
EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryoversNotRecognized
-0.304
CY2016 toca Effective Income Tax Rate Reconciliation Net Operating Loss Carryovers Not Recognized
EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryoversNotRecognized
-0.328
CY2015 toca Effective Income Tax Rate Reconciliation Net Operating Loss Carryovers Not Recognized
EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryoversNotRecognized
-0.333
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.010
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.011
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.017
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.001
CY2016 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.003
CY2015 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.002
CY2017Q4 toca Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
52000
CY2016Q4 toca Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
52000
CY2017Q4 toca Deferred Tax Assets Deferred License Revenue
DeferredTaxAssetsDeferredLicenseRevenue
15000
CY2016Q4 toca Deferred Tax Assets Deferred License Revenue
DeferredTaxAssetsDeferredLicenseRevenue
38000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1459000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1062000
CY2017Q4 toca Deferred Tax Assets Accrued Liabilities And Other
DeferredTaxAssetsAccruedLiabilitiesAndOther
808000
CY2016Q4 toca Deferred Tax Assets Accrued Liabilities And Other
DeferredTaxAssetsAccruedLiabilitiesAndOther
796000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
2334000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
1948000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2334000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1948000
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
400000
CY2016 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
400000
CY2017Q4 toca Cumulative Change In Ownership Percentage
CumulativeChangeInOwnershipPercentage
0.50
CY2017 toca Period For Cumulative Change In Ownership
PeriodForCumulativeChangeInOwnership
P3Y
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
31800000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
24200000
CY2017Q4 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
0
CY2016Q4 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
0
CY2017Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued
0
CY2016Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued
0
CY2017 toca Tax Cuts And Jobs Act Of2017 Incomplete Accounting Provisional Income Tax Expense Benefit Related To Deferred Tax Asset
TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefitRelatedToDeferredTaxAsset
1400000
CY2017 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
0
CY2016Q4 us-gaap Operating Expenses
OperatingExpenses
7985000
CY2016 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
0
CY2015 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
0
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
8564000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-9073000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.11
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
7580000
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
7633000
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
8542000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-8006000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-8042000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-9000000
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-8430000
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.64
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.66
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.09
CY2016Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.83

Files In Submission

Name View Source Status
0001564590-18-005132-index-headers.html Edgar Link pending
0001564590-18-005132-index.html Edgar Link pending
0001564590-18-005132.txt Edgar Link pending
0001564590-18-005132-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g2018030919455568151622.jpg Edgar Link pending
g2018030919455569851623.jpg Edgar Link pending
g2018030919455571251624.jpg Edgar Link pending
g2018030919455573251625.jpg Edgar Link pending
g2018030919455625651626.jpg Edgar Link pending
g2018030919455627351627.jpg Edgar Link pending
g2018030919460225449550.jpg Edgar Link pending
g2018030919460263749551.jpg Edgar Link pending
g2018030919460264649552.jpg Edgar Link pending
g2018030919460281949553.jpg Edgar Link pending
g2018030919460325849554.jpg Edgar Link pending
g2018030919460370849555.jpg Edgar Link pending
g2018030919461526149556.jpg Edgar Link pending
g2018030919472538052389.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
toca-10k_20171231.htm Edgar Link pending
toca-20171231.xml Edgar Link completed
toca-20171231.xsd Edgar Link pending
toca-20171231_cal.xml Edgar Link unprocessable
toca-20171231_def.xml Edgar Link unprocessable
toca-20171231_lab.xml Edgar Link unprocessable
toca-20171231_pre.xml Edgar Link unprocessable
toca-ex1011_793.htm Edgar Link pending
toca-ex1012_768.htm Edgar Link pending
toca-ex1013_767.htm Edgar Link pending
toca-ex1014_766.htm Edgar Link pending
toca-ex1015_765.htm Edgar Link pending
toca-ex1016_769.htm Edgar Link pending
toca-ex1017_876.htm Edgar Link pending
toca-ex231_1053.htm Edgar Link pending
toca-ex311_9.htm Edgar Link pending
toca-ex312_8.htm Edgar Link pending
toca-ex321_7.htm Edgar Link pending
toca-ex322_6.htm Edgar Link pending